Mediclinic International Future Growth

Future criteria checks 2/6

Mediclinic International is forecast to grow earnings and revenue by 10.7% and 3.6% per annum respectively. EPS is expected to grow by 12.2% per annum. Return on equity is forecast to be 6.6% in 3 years.

Key information

10.7%

Earnings growth rate

12.2%

EPS growth rate

Healthcare earnings growth	27.8%
Revenue growth rate	3.6%
Future return on equity	6.6%
Analyst coverage	Good
Last updated	30 May 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

JSE:MEI - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	3,888	271	N/A	N/A	1
3/31/2025	3,684	255	330	551	6
3/31/2024	3,564	237	309	525	6
3/31/2023	3,441	212	183	422	6
9/30/2022	3,383	169	283	470	N/A
6/30/2022	3,308	160	329	512	N/A
3/31/2022	3,233	151	375	554	N/A
12/31/2021	3,199	135	321	483	N/A
9/30/2021	3,165	118	266	412	N/A
6/30/2021	3,080	93	183	324	N/A
3/31/2021	2,995	68	99	235	N/A
12/31/2020	2,987	-173	N/A	N/A	N/A
9/30/2020	2,979	-414	133	306	N/A
6/30/2020	3,031	-367	203	381	N/A
3/31/2020	3,083	-320	273	456	N/A
12/31/2019	3,070	-97	N/A	N/A	N/A
9/30/2019	3,057	126	246	443	N/A
6/30/2019	2,995	-12	175	394	N/A
3/31/2019	2,932	-151	104	344	N/A
12/31/2018	2,897	-380	N/A	N/A	N/A
9/30/2018	2,861	-610	23	277	N/A
6/30/2018	2,869	-551	57	311	N/A
3/31/2018	2,876	-492	91	345	N/A
12/31/2017	2,874	-211	N/A	N/A	N/A
9/30/2017	2,871	69	97	350	N/A
6/30/2017	2,810	149	121	364	N/A
3/31/2017	2,749	229	145	377	N/A
12/31/2016	2,565	210	155	375	N/A
9/30/2016	2,380	191	165	373	N/A
6/30/2016	2,244	184	N/A	347	N/A
3/31/2016	2,107	177	N/A	320	N/A
12/31/2015	2,080	211	N/A	314	N/A
9/30/2015	2,183	257	N/A	330	N/A
6/30/2015	2,042	245	N/A	327	N/A
3/31/2015	1,977	241	N/A	337	N/A
12/31/2014	1,901	221	N/A	312	N/A
9/30/2014	1,810	199	N/A	284	N/A
6/30/2014	1,751	193	N/A	270	N/A
3/31/2014	1,738	193	N/A	263	N/A
12/31/2013	1,652	82	N/A	253	N/A
9/30/2013	1,653	-33	N/A	257	N/A
6/30/2013	1,701	-55	N/A	256	N/A
3/31/2013	1,742	-79	N/A	253	N/A
12/31/2012	1,729	19	N/A	232	N/A
9/30/2012	1,730	118	N/A	213	N/A
6/30/2012	1,759	109	N/A	198	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEI's forecast earnings growth (10.7% per year) is above the savings rate (9.3%).

Earnings vs Market: MEI's earnings (10.7% per year) are forecast to grow faster than the ZA market (10.1% per year).

High Growth Earnings: MEI's earnings are forecast to grow, but not significantly.

Revenue vs Market: MEI's revenue (3.6% per year) is forecast to grow slower than the ZA market (4.9% per year).

High Growth Revenue: MEI's revenue (3.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MEI's Return on Equity is forecast to be low in 3 years time (6.6%).

Mediclinic International Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Mediclinic International plc Provides Revenue Guidance for Fiscal 2022

Recent updates

Financial Conduct Authority Cancels the Listing of Mediclinic Shares on the London Stock Exchange and Delisting of Shares from the JSE and the NSX Expects to Take Effect on 7 June 2023

Mediclinic International's Cancellation of Shares from Official List and Main Market of LSE Expected to Take on 30 May 2023; Delisting of Shares from JSE and NSX Expected to Take Effect from Commencement of Trade on 7 June 2023

Mediclinic International plc(LSE:MDC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Cancellation of Listing of Mediclinic Shares on the LSE Is Expected on 26 May 2023

Mediclinic International plc (LSE:MDC) acquired Artisan Biomed.

Mediclinic International plc Approves Final Cash Dividend, Payable on 26 August 2022

Mediclinic International plc to Delist

Mediclinic International plc Approves Final Cash Dividend

Upcoming dividend of R0.60 per share

Remgro Wants Equal Partner in Possible Mediclinic Buyout

Mediclinic International Ordinary Shares to Be Deleted from OTC Equity

Independent Non-Executive Director recently bought R1.4m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Mediclinic International plc to Report First Half, 2023 Results on Nov 16, 2022

High number of new directors

Mediclinic International plc to Report Fiscal Year 2022 Results on May 25, 2022

High number of new directors

High number of new directors

First half 2022 earnings released: EPS UK£0.088 (vs UK£0.02 in 1H 2021)

High number of new directors

High number of new directors

Senior Independent Director J. Grieve has left the company

Independent Non-Executive Director Trevor Petersen has left the company

Group CEO & Executive Director recently bought R570k worth of stock

Full year 2021 earnings released: EPS UK£0.092 (vs UK£0.43 loss in FY 2020)

Mediclinic International plc Provides Revenue Guidance for Fiscal 2022

New 90-day high: R63.35

Non-Executive Director recently sold R1.1m worth of stock

New 90-day low: R55.84

First half 2021 earnings released: EPS UK£0.02

Revenue beats expectations, earnings disappoint

New 90-day high: R68.45

New 90-day high: R63.13

New 90-day low - R53.50

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies